CD19 and hematologic disorder: Here we report interim results from CLIC-01, a single-arm, open-label phase I/II study (NCT03765177) to evaluate the safety and efficacy of our CLIC-1901 non-cryopreserved CAR-T cell product in participants with CD19 positive hematologic malignancies.